

PRESS RELEASE

TauRx Pharmaceuticals organises Information Meeting for Alzheimer Europe members


On Wednesday 14th September, TauRx Pharmaceuticals Ltd, a global leader in tau-based research in Alzheimer's disease (AD), presented to members of the Alzheimer Europe umbrella organisation. The session focused on providing an update on the company's clinical trial progress, tau pathology and therapeutic approaches to this important target in Alzheimer's disease, and a detailed discussion between all attendees on how best to support the dissemination of research information to people with dementia, their families, and carers.

As the world awaits a significant therapeutic breakthrough for Alzheimer's, post-diagnostic support for people with dementia is centre stage for this World Alzheimer's Month. As part of this, being able to share important updates on LUCIDITY trial progress and outcomes is critical. TauRx invited attendees of the meeting to offer insights on what they understand the people with dementia want to learn about.

"Understanding what people need on a practical level following a diagnosis of Alzheimer's is of utmost importance," explains Dr Sonya Miller, Head of Medical Affairs and Clinical Safety Oversight Lead at TauRx. "A diagnosis is often the trigger for a complex system of therapy, care, and extended support necessary to allow people to live well with dementia and reduce the burden of the disease.

"Whilst we all continue to work towards a safe, effective, and affordable therapeutic answer to Alzheimer's, the research industry must continue to find ways to help organisations such as Alzheimer Europe and its members to educate on progress in the field and share the latest information concerning clinical trials."

"TauRx adds to this educational effort by sharing its decades of expertise in tau science and dedicated focus on neurodegenerative disease. But we must not make assumptions, and we learn more by asking questions in this forum to ensure we provide the right level of information and support that will benefit the patients and caregivers who need it most."





About Alzheimer Europe

Alzheimer Europe is the umbrella organisation of national Alzheimer associations throughout Europe. Alzheimer Europe sees its mission as changing perceptions, policy and practice in order to improve the lives of people affected by dementia.

Email: info@alzheimer-europe.org

Website: www.alzheimer-europe.org

About TauRx Pharmaceuticals Ltd

TauRx group of companies was established in 2002 in Singapore, continuing a partnership with the University of Aberdeen, with primary research facilities and operation based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer's and other neurodegenerative diseases due to protein aggregation pathology.

Tau aggregation and the subsequent formation of tau tangles disrupts neuronal function, a process that begins many years before symptoms of dementia are seen. Tau pathology correlates strongly with Alzheimer's severity and the clinical decline, which often manifests as loss of memory and ability to care for oneself.

The current Phase 3 clinical trial, LUCIDITY, is the only late-stage clinical trial specifically targeting the tau pathology of Alzheimer's. The trial is a 2-year study, which is currently approximately halfway through the final year open label phase and due to complete in mid-2023. More information can be found here: www.luciditytrial.com.

<https://www.taurx.com>

Contact: Rebecca Andersen, Head of Commercial and Communications
r.andersen@taurx.com

